Apollo-managed funds and affiliates will acquire a minority, non-controlling stake in a newly established entity
The acquisition brings together Novartis’ global oncology capabilities with Myricx Bio’s pioneering N-myristoyltransferase inhibitor (NMTi) payload platform
The drug is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa IntraMuscular Injection
The India FMCG business maintained its growth momentum during the quarter
Meanwhile, US-based facilities have seen their share remain unchanged at 18% since 2024
This prestigious certification is based entirely on the experiences shared by current employees of the company
A final decision from the European Commission is expected in the coming months
The new facility increases the company's xanthine derivatives manufacturing capacity to 9,600 TPA, positioning Aarti Pharmalabs among the world's top three manufacturers in the segment
The collaboration aims to shorten early drug discovery timelines, improve the quality of lead candidates, and increase the likelihood of clinical success by enabling better decision-making
The launch of Rashfree Eva cream and spray extends the brand beyond baby care, offering targeted solutions for skin rashes, chafing, and diaper-related irritation in women and elderly adults
The company has completed its first commercial dispatch worth Rs. 50 crore and expects supplies of around Rs. 225 crore in the second quarter
NaMuscla is the only approved treatment for myotonia symptoms in NDM in Europe
Unveiled at the BIO International Convention 2026, the initiative brings together leaders from pharma, biotech, academia, government, investment, and patient advocacy
The Great Place to Work India recognition makes Aragen the first and only Indian CRDMO to feature among the country’s top list, highlighting its people-first workplace culture.
Voyageur has budgeted US$2,350,000 for completion of the Bayer project feasibility study and will create a final budget for the integrated iodine and barium drug facility feasibility study
The deal marks a strategic expansion for Jagsonpal into the hospital segment
This acquisition further strengthens our late-stage oncology pipeline
Subscribe To Our Newsletter & Stay Updated
